List view / Grid view
The tablet formulation for AstraZeneca’s BTK inhibitor has gained EU…
The tablet formulation for AstraZeneca’s BTK inhibitor has gained EU approval for co-administration with gastric acid-reducing agents in chronic lymphocytic leukaemia patients.
The European Commission has approved Enhertu in the EU as…
The European Commission has approved Enhertu in the EU as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer.
Patients in the EU with an advanced prostate cancer will…
Patients in the EU with an advanced prostate cancer will benefit from a newly approved Lynparza-based treatment combination for the first time.
New data shows AstraZeneca’s Imfinzi (durvalumab) achieved an unprecedented five…
New data shows AstraZeneca’s Imfinzi (durvalumab) achieved an unprecedented five year survival rate of over 40 percent in patients with Stage III non-small cell lung cancer.
In the Phase III OlympiA trial, Lynparza® (olaparib) reduced the…
In the Phase III OlympiA trial, Lynparza® (olaparib) reduced the risk of cancer recurrences or death by 42 percent in patients with BRCA-mutated high-risk early breast cancer.
Imfinzi (durvalumab) has been approved by the European Commission as…
Imfinzi (durvalumab) has been approved by the European Commission as a first-line treatment for extensive-stage small cell lung cancer, with chemotherapy.
Lynparza’s approval was based on results from a Phase III…
Lynparza’s approval was based on results from a Phase III clinical trial in which it improved overall survival and progression-free survival in patients with certain prostate cancers.
Following positive clinical trials, the Tagrisso drug has been given…
Following positive clinical trials, the Tagrisso drug has been given marketing authorisation in China for treatment of NSCLC.
BRCA-mutated advanced ovarian cancer treatment has been approved by the…
BRCA-mutated advanced ovarian cancer treatment has been approved by the European Commission.
